Remicade biosim floats through EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has given Hospira/Celltrion's version of J&J/Merck & Co's anti-TNF monoclonal antibody Remicade (infliximab) the formal green light after what seems to have been a very smooth approval process.